Rocket Pharmaceuticals (RCKT) EBITDA (2014 - 2026)

Rocket Pharmaceuticals has reported EBITDA for 13 years, with the latest figure at -$48.5 million in Q1 2026.

• Quarterly EBITDA rose 24.66% year-over-year to -$48.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$215.9 million (up 20.11% YoY) and the FY2025 annual result came in at -$231.7 million, up 15.17% from the prior year.
• EBITDA eased to -$48.5 million in Q1 2026 per RCKT's latest filing, from -$44.0 million in the prior quarter.
• Over five years, EBITDA peaked at -$42.6 million in Q1 2022 and troughed at -$73.7 million in Q2 2024.
• A 5-year average of -$61.0 million and a median of -$63.3 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2025: EBITDA sank 59.22% in 2022, then grew 29.88% in 2025.
• Over 5 years, EBITDA stood at -$69.1 million in 2022, then increased by 8.4% to -$63.3 million in 2023, then climbed by 0.92% to -$62.7 million in 2024, then advanced by 29.88% to -$44.0 million in 2025, then dropped by 10.35% to -$48.5 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$48.5 million, -$44.0 million, and -$52.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.